Hatem Soliman, MD

“The updated long-term follow-up from IBIS II showed that tamoxifen and anastrozole have similar efficacy in preventing breast cancer recurrences in patients diagnosed with ductal carcinoma in situ. However, there were differences in side effects consistent with the known safety profiles of these agents. These data, along with results from NSABP B-35, allow providers to engage in shared decision-making with a patient about both treatments and select the drug best suited for their particular medical circumstances,” said Hatem Soliman, MD, a medical oncologist in the Breast Oncology Department, Moffitt Cancer Center, Tampa, Florida. 

DISCLOSURE: Dr. Soliman reported no conflicts of interest.